Breast cancer patients treated with a combination of medicines that included an experimental pill from Seattle Genetics experienced significantly delayed tumor growth and improved survival compared to standard therapy alone, according to Phase 3 clinical trial results announced Monday.
Based on the results, Seattle Genetics intends to file a marketing application for the drug, called tucatinib, with the Food and Drug Administration early next year, the company said.
About the Author Reprints
